A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F19%3A00078347" target="_blank" >RIV/00209805:_____/19:00078347 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14740/19:00112969
Result on the web
<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827047/" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827047/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/cancers11101618" target="_blank" >10.3390/cancers11101618</a>
Alternative languages
Result language
angličtina
Original language name
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Original language description
The mitogen-activated protein kinase (MAPK) pathway is an important bridge in the switch from extracellular signals to intracellular responses. Alterations of signaling cascades are found in various diseases, including cancer, as a result of genetic and epigenetic changes. Numerous studies focused on both the homeostatic and the pathologic conduct of MAPK signaling; however, there is still much to be deciphered in terms of regulation and action models in both preclinical and clinical research. MAPK has implications in the response to cancer therapy, particularly the activation of the compensatory pathways in response to experimental MAPK inhibition. The present paper discusses new insights into MAPK as a complex cell signaling pathway with roles in the sustenance of cellular normal conduit, response to cancer therapy, and activation of compensatory pathways. Unfortunately, most MAPK inhibitors trigger resistance due to the activation of compensatory feed-back loops in tumor cells and tumor microenvironment components. Therefore, novel combinatorial therapies have to be implemented for cancer management in order to restrict the possibility of alternative pathway activation, as a perspective for developing novel therapies based on integration in translational studies.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancers (Basel)
ISSN
2072-6694
e-ISSN
—
Volume of the periodical
11
Issue of the periodical within the volume
10
Country of publishing house
CH - SWITZERLAND
Number of pages
25
Pages from-to
1618
UT code for WoS article
000498826000215
EID of the result in the Scopus database
2-s2.0-85074947906